ALK and cancer: Atezolizumab was also combined with platinum-based chemotherapy in the phase III IMpower 150 clinical study, which evaluated the efficacy of the drug in association with carboplatin, paclitaxel and bevacizumab-based chemotherapy in patients with untreated advanced NSCLC, including cancers with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations [26].